Copyright © 2005 American Medical Association. All rights reserved. From: Response to Interferon Beta-1a Treatment in African American Multiple Sclerosis Patients Arch Neurol. 2005;62(11):1681-1683. doi:10.1001/archneur.62.11.1681 Figure Legend: The African American (AA) subjects had more exacerbations than the white American (WA) subjects after 24 weeks (P = .06) and 48 weeks (P = .13) of treatment with interferon beta-1a. Date of download: 10/24/2017 Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved. From: Response to Interferon Beta-1a Treatment in African American Multiple Sclerosis Patients Arch Neurol. 2005;62(11):1681-1683. doi:10.1001/archneur.62.11.1681 Figure Legend: The African American (AA) subjects were less likely than the white American (WA) subjects to remain relapse free after 24 weeks (P = .07) and 48 weeks (P = .24) of treatment with interferon beta-1a. Date of download: 10/24/2017 Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved. From: Response to Interferon Beta-1a Treatment in African American Multiple Sclerosis Patients Arch Neurol. 2005;62(11):1681-1683. doi:10.1001/archneur.62.11.1681 Figure Legend: The African American (AA) subjects had more new lesions than the white American (WA) subjects at 24 weeks (P = .15) and 48 weeks (P = .04). Date of download: 10/24/2017 Copyright © 2005 American Medical Association. All rights reserved.